Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Oct 10, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 third quarter financial results before the opening of the market on Thursday October 19, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on October 19, 2017 to discuss its ...
Sep 5, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO) today announced it will be a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017, at Lotte New York Palace Hotel ...
Aug 31, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present two scientific posters at the upcoming PAINWeek national conference to be held in Las Vegas, NV, September 5-9. Both studies leveraged the Quell® Health Cloud, which connects with t...
Aug 29, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- In recognition of Pain Awareness Month this September, NeuroMetrix, Inc. (Nasdaq: NURO) is partnering with the U.S. Pain Foundation, a nonprofit organization dedicated to serving those who live with pain conditions and their providers, to raise awareness of the issues im...
Aug 15, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,731,126. The patent covers novel technology whereby the Quell® device automatically modulates therapeutic neurostimulation based on the user's sle...
Aug 3, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported an agreement with Fukuda Denshi for DPNCheck® distribution in Japan. DPNCheck is NeuroMetrix' rapid, accurate, and quantitative point-of-care test to detect diabetic peripheral neuropathy. Diabetes is a serious health ...
Jul 27, 2017 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported today that it had shipped its 100,000th Quell® wearable device for treatment of chronic pain since commercial launch in mid-2015. Quell device shipments have posted growth in each of the eight sequential quarters that it has been on...
Jul 20, 2017 Revenue of $4.3M is up 63% year-over-year Quell device shipments of 20.1K and electrode reorders of 30.7K represent new quarterly highs DPNCheck revenue of $0.8 million is up 78% year-over-year WALTHAM, Mass.--(BUSINESS WIRE)-- ...
Jul 13, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 second quarter financial results before the opening of the market on Thursday July 20, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on July 20, 2017 to discuss its ...
Jul 10, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it has entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 7,000 shares of Series F convertible preferred stock at a price ...
Jul 6, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that Michael MacDonald has been promoted to SVP and General Manager of Diagnostics. In this role, Mr. MacDonald will oversee the Company's diagnostic products which include DPNCheck® and ADVANCE™. ...
Jun 26, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its data science initiative and the related Quell® Health Cloud. Data science consists of the development of large cloud databases and the use of powerful analytical tools such as machine learning a...
Jun 23, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its Quell® clinical program. Quell is a wearable non-invasive neurostimulator that provides widespread analgesia for chronic pain. In addition to delivery of therapy, the device and its associated smartphone app tr...
Jun 13, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,675,801. The patent covers novel mechanisms to help Quell® users safely obtain pain relief therapy over prolonged time periods. More ...
Jun 8, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix, is scheduled to speak at the upcoming 2017 Marcum Microcap Conference at the Grand Hyatt Hotel in New York City. Dr. Gozani intends to provide an update on the ...
Jun 6, 2017 Waltham-based company to exhibit its wearable device for widespread chronic pain relief BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) is showing Quell®, its 100% drug-free Wearable Pain Relief Technology™ to sleep medicine professionals from around t...
May 30, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix, is scheduled to speak at the upcoming LD Micro Invitational at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr. Gozani intends to provide an update on the ...
May 22, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,656,070. The patent covers the novel application of real-time accelerometer measurements to control transcutaneous electrical nerve stimulation....
May 17, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO) announced that it was the recipient of the Smaller Businesses Association of New England (SBANE) New England Innovation Award for the development and successful launch of Quell® Wearable Pain Relief Technology™. Previous winners of this ...
May 16, 2017 Blog to serve as a resource on issues and topics related to chronic pain, such as digital medicine and alternative treatments WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the launch of LivingQuell, a blog that will serve as an online resource fo...
May 15, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that researchers from the University of Rochester School of Medicine and Dentistry will present a scientific poster titled "Wearable TENs band for chemotherapy-induced peripheral neuropathy (CIPN): A feasibility study" at t...
May 11, 2017 Shares of Common Stock and Certain Warrants Will Begin Trading on a Split-Adjusted Basis on May 12, 2017 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced a one-for-eight reverse split of its common stock effective as of Thursday, May 11, 2017. The shares und...
May 8, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported today that Notices of Allowance has been issued for patents covering key technological features of the Company's Quell® Wearable Pain Relief Technology™ by the European Patent Office, the Japan Patent Office, and the S...
May 5, 2017 Early adopters come together to dialog with the makers of the Quell wearable technology. WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) held its first Quell® Wearable Pain Relief Technology™ user event last Thursday, April 27. As a cust...
Apr 20, 2017 Revenue of $4.3M is up 89% year-over-year Quell device shipments of 18.7K and electrode reorders of 25.4K represent new quarterly highs Quell retail availability expands to nearly 3,000 stores WALTHAM, Mass.--(BUSINESS WIRE)-- ...
Apr 18, 2017 Waltham-based company expands availability into brick-and-mortar locations of leading domestic and home merchandise retailer WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the availability of its flagship product, Quell®, at select number of ...
Apr 13, 2017 Inaugural initiative of AARP and MedCity News showcases companies and people delivering cutting-edge healthcare solutions for the 50+ market MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it was selected as one of the healthcare...
Apr 12, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2017 first quarter financial results before the opening of the market on Thursday, April 20, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on April 20, 2017 to discuss its ...
Mar 15, 2017 Waltham-based company to exhibit its wearable device for widespread pain relief ORLANDO, Fla.--(BUSINESS WIRE)-- Coming together with thousands of leading clinicians who treat patients with chronic pain, NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell®, its FDA-cle...
Mar 1, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported increased media attention in 2017 on the company's Quell® Wearable Pain Relief Technology™. An Inside Look at the Latest Health Tech - The Dr. Oz Show 3 Amazing New G...
Feb 21, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell® will be available in over 450 Best Buy® stores nationwide beginning in mid-February and is now available for purchase on BestBuy.com. "More and more consumers are proactively looking for techno...
Jan 26, 2017 2016 revenue $12.0M up 65% year-on-year; Q4 revenue $3.7M up 36% Quell device shipments of 14.3K and electrode reorders of 20K represent new quarterly highs WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW), today reported financial a...
Jan 20, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO, NUROW) announced today that it plans to issue its 2016 full year and fourth quarter financial results before the opening of the market on January 26, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on January 26, 2017 to ...
Jan 10, 2017 Invoiced Value of Quell Shipments Up 19% Over Q3 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO, NUROW) reported Q4 2016 demand highlights for its Quell® Wearable Pain Relief Technology™. During Q4 2016 the invoiced value of Quell shipments ...
Jan 6, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO, NUROW) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Digital Medicine Showcase 2017 at the Parc 55 San Francisco in San Francisco, CA. The Digital Medicine Showcase brings ...
Jan 5, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO, NUROW) announced that it has closed its previously announced private placement to a healthcare dedicated institutional investor of 7,000 shares of Series E convertible preferred stock at a price of $1,000 per share, and warrants to purchase an ...
Jan 3, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the Biotech Showcase 2017 Conference being held at the Hilton San Francisco Union Square in San Francisco, CA. Dr. Gozani...
Jan 3, 2017 Company unveils advanced product features for Quell Wearable Pain Relief Technology at CES 2017, booth #43421 LAS VEGAS--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO, NUROW) today announced plans to unveil important advances to its Quell® Wearable Pain Relie...
Dec 28, 2016 Will not complete previously announced registered offering WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO, NUROW) announced today that it has entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a pri...
Dec 22, 2016 Company to Unveil Innovative Upgrades for Quell Wearable Pain Relief Technology LAS VEGAS--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) Building on sales to over 50,000 chronic pain sufferers who have tried Quell® since its launch in June 2015, NeuroMetrix...
Dec 20, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. ("NeuroMetrix" or the "Company") (NASDAQ: NURO, NUROW) announced today the pricing of a public offering with expected gross proceeds from the offering of $26.5 million. The offering was priced at $0.70 per share of the Company's common stock (or common stock ...
Dec 15, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) reported increased media attention on the company's Quell® Wearable Pain Relief Technology™, including an in depth report on CBS's Innovation Nation. Highlights include: CBS Innovation Nation - The ...
Dec 13, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that its Quell® Wearable Pain Relief Technology™ is featured in the new Thrive Global commerce platform, including the online store at ThriveGlobal.com and Retail Pop Up Experience in New York City from December 1...
Dec 12, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix will speak on using personal connected health for pain, addiction, and healing at the 2016 Connected Health Conference to take place Monday, Decembe...
Dec 7, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that the Company's Quell® Wearable Pain Relief device is now available on Amazon Launchpad. Amazon Launchpad is a program that makes it easy for startups to launch, market, and distribute their ...
Nov 30, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO, NUROW) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the upcoming LD Micro Invitational at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr. Gozani intends to provide an update ...
Nov 29, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that the CE (Conformité Européenne) Certificate for Quell® has been received from TŰV SŰD Product Service GmbH, which is one of the Notified Bodies responsible for reviewing and approving new product...
Nov 22, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO,NUROW) announced today that its Quell® Wearable Pain Relief Technology™ will be featured on the November 26th episode of The Henry Ford Innovation Nation which airs on the CBS network on Saturday mornings as part of its "CBS Dream ...
Nov 16, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Quell® Wearable Pain Relief Technology™ will be featured for the second year in a row at the American Society for Regional Anesthesia's Annual Pain Medicine Meeting to be held November 17-19 in San Diego, CA....
Nov 15, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) today reported that DPNCheck®, a diagnostic test for peripheral neuropathy, will be introduced at the 20th Scientific Meeting of the Chinese Diabetes Society during November 16-19, 2016 in Xiamen, Fujian, China. DPNCheck is registered ...
Nov 10, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Senior Vice President and Chief Commercial Officer Frank McGillin will present on Quell® Wearable Pain Relief Technology™ during the 16th Annual Diabetes Technology Meeting, November 10-12, in Bethesda, ...
Nov 8, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that it has promoted Frank McGillin to Senior Vice President and Chief Commercial Officer. Mr. McGillin's most recent title was Senior Vice President and GM Consumer. In the expanded role, Mr. McGillin will have primary ...
Oct 27, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,474,898. The patent covers key technology that enables safe delivery of Quell® therapy for chronic pain while the user is sleeping. Over 80% of chro...
Oct 25, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO, NUROW) announced today that Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix, is scheduled to speak at the 2016 Sidoti Emerging Growth Convention at the Marriott Marquis in New York City on November 1, 2016...
Oct 20, 2016 Revenue up 65% year-over-year to $3.4 Million New quarterly highs for Quell device shipments and electrode reorders DPNCheck shipments reached 4 year high of 57,400 biosensors WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc....
Oct 18, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) reported today that it will be an active participant at the Connected Health Symposium on October 20-21 in Boston sponsored by Partners Healthcare. Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix, will be a panelist for a discu...
Oct 13, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that it plans to issue its 2016 third quarter financial results before the opening of the market on Thursday, October 20, 2016. The Company will host a conference call at 8:00 a.m., Eastern Time on October 20, 2016 to discus...
Oct 10, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) reported today that it has been selected to showcase Quell® Wearable Pain Relief Technology™ at the Discover Blue: New York City event hosted by the Bluetooth Special Interest Group on October 12th. "We'r...
Oct 6, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) today announced that Dr. Xuan Kong, SVP, Research and Intellectual Property, will present the Company's DPNCheck® technology at the 5th Annual Diabetic Peripheral Neuropathy Fellowship for Chinese Physicians at the University ...
Oct 5, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) today announced a clinical study of Quell® Wearable Pain Relief Technology™ in patients with chronic low back pain at the Brigham and Women's Hospital Pain Management Center. According to the Centers for ...
Sep 28, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced that Frank McGillin, Senior Vice President and General Manger, Consumer, will participate in a panel discussion on the THE DIGITAL HEALTHCARE REVOLUTION at the Wearable Technology Show in Santa Clara, CA on October 5th. M...
Sep 22, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Synovation Medical Group will conduct an evaluation of Quell® Wearable Pain Relief Technology™ in fibromyalgia patients. "We have seen both clinical data and positive reviews that suggest that...
Sep 20, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) reported today on multiple efforts to increase the availability of Quell® Wearable Pain Relief Technology™ to veterans who suffer from chronic pain through the Veterans Health Administration. The Company ...
Sep 16, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that the Company's Quell® Wearable Pain Relief Technology™ has won the Electronics Retailer Association Moxie Award for the Best Health Show 2016. This Moxie award recognizes the year's best direct response telev...
Sep 13, 2016 Omron Leading Local Initiatives WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported final regulatory approval in China for DPNCheck®, a diagnostic test for peripheral neuropathy. DPNCheck is registered as a Class II Medical Device with the China Fo...
Sep 8, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Comprehensive Pain Specialists will offer Quell® Wearable Pain Relief Technology™ in selected clinic locations. "We are pleased that a growing number of forward-thinking pain management prov...
Sep 6, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016, at Lotte New York ...
Sep 1, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the State Intellectual Property Office of the People's Republic of China has issued Chinese Patent No. ZL20118055305.7 for the core technology underlying the Company's DPNCheck® device, which is a point-of-care t...
Aug 30, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced the launch of a new website to promote Quell®, the company's rapidly growing pain relief brand. The new site reflects NeuroMetrix' focus on helping people with chronic pain reclaim their lives. The Quel...
Aug 25, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell® will be featured in the Target Open House in San Francisco. "We are delighted that Target has added Quell to their Open House concept," said Frank McGillin, SVP and General Manager, Consume...
Aug 22, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that to celebrate having reached 10,000 fans for Quell® Pain Relief on Facebook, it will give away a contest prize each day during September which is Pain Awareness Month. Consumers are encouraged to follow the Quell Facebook ...
Aug 16, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today provided commentary on its Quell® partnership strategy. The Company has five objectives for its Quell partnership strategy. Support NeuroMetrix efforts to build the Quell brand in the North ...
Aug 3, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that the company, in partnership with Advantage Healthcare, will explore Quell® retail expansion plans with executives from key national and regional drug chains and mass merchandisers at the NCADS Total Store Expo taking place...
Aug 2, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced a major milestone with over 1 million hours of Quell® therapy and health data uploaded to the Quell Health Cloud as of August 1, 2016. Quell is a wearable therapeutic technology that provides drug-free relief from chronic pain ...
Jul 28, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today reported continued strong media attention focusing on the company's innovative Quell® Wearable Pain Relief Technology™. Highlights include: Forbes - Can this wearable device really zap away ch...
Jul 21, 2016 Revenue Up 116% year-over-year to $2.6 Million 11,201 Quell Devices Shipped Expanded Retail Availability of Quell to over 1,500 retail stores WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and...
Jul 14, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2016 second quarter financial results before the opening of the market on Thursday July 21, 2016. The Company will host a conference call at 8:00 a.m., Eastern Time on July 21, 2016 to discuss its ...
Jul 13, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NURO) today reported commercial expansion of DPNCheck® in Mexico following receipt of a purchase order from one of Mexico's six major government healthcare institutions. With this most recent order, two of these six major institutions have now ado...
Jul 12, 2016 100% Drug Free, FDA Cleared Wearable for Widespread Relief from Chronic Pain WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell® Wearable Pain Relief Technology™ will be featured for the second year in a row at the American Podiat...
Jul 7, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced commercial launch of a new Sport Electrode for its innovative Quell® Wearable Pain Relief Technology™. The new electrode has a special hydrogel designed to better hold up in situations with high humidity and perspiration...
Jul 6, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported publication of the initial Quell® study in the Journal of Pain Research. The paper is titled "Fixed-Site High-Frequency Transcutaneous Electrical Nerve Stimulation for Treatment of Chronic Low Back and Lower Extremity ...
Jun 28, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that WBC Group, LLC will be the exclusive distributor of Quell® Wearable Pain Relief Technology™ to chiropractors, physical therapists, physical fitness facilities and personal trainers through their MeyerDC, Me...
Jun 27, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) and the Scripps Translational Science Institute (STSI) today announced a clinical study of Quell® wearable pain relief technology in patients with cancer related pain. According to the National Cancer Institute, about 15 milli...
Jun 22, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that a CE (Conformité Européenne) Technical File Application for Quell® has been submitted to TŰV SŰD Product Service GmbH, which is one of the Notified Bodies responsible for reviewing and approving new pr...
Jun 21, 2016 100% Drug Free, FDA Cleared Wearable for Widespread Relief from Chronic Pain WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell® Wearable Pain Relief Technology™ will be featured at the Western Foot & Ankle Conference to be held J...
Jun 14, 2016 WALTHAM, Mass.--(BUSINESS WIRE)--  NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell® Wearable Pain Relief Technology™ is available in Canada via Amazon Canada. "Canadian consumers have been asking for easier access to Quell," said Frank McGillin, SVP and General Mana...
Jun 10, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) which developed and markets Quell® Wearable Pain Relief Technology™, reported purchases during May 2016 of the company's common stock by its Chief Executive Officer, Dr. Shai N. Gozani; its Chief Financial Officer, Thomas T. Higgins; an...
Jun 9, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell® Wearable Pain Relief Technology™ will be featured at SLEEP 2016, which is a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. The meeting takes place June 11-15 in Denver,...
Jun 8, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported that it has closed its previously announced private placement of preferred stock and warrants. The Company sold to a healthcare dedicated institutional investor 21,300 shares of Series D convertible preferred stock at a price of $1,000 pe...
Jun 6, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it is celebrating its twenty year anniversary. NeuroMetrix was incorporated in Cambridge, Massachusetts on June 6, 1996 as a spin-off from the Harvard-MIT Division of Health Sciences and Technology. Th...
Jun 2, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 21,300 shares of Series C convertible preferred stock at a price of $1,000...
Jun 2, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell® will be available, beginning in June 2016, in approximately 1,000 chain drug stores as part of a retail test with the two largest US drug retailers. "Consumers have told us that they expect...
May 31, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the upcoming LD Micro Invitational at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr. Gozani intends to provide an update on the ...
May 26, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), announced today the launch of the Quell Health Cloud for Android The updated Android app allows consumers to set up accounts on the Quell Health Cloud where their data is automatically backed-up to secure storage. This eliminates consumer ...
May 18, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced that Frank McGillin, Senior Vice President and General Manager, Consumer will participate in a panel discussion entitled "The Rise of Enterprise & Condition-Specific Wearables" during the Fifth Annual Digital Health Summer Summit. Digita...
May 16, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that Quell® is now available at Brookstone.com. "Brookstone is known for selling leading edge technology," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "We are pleased to be worki...
May 12, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) has launched national television advertising to promote the company's innovative Quell® Wearable Pain Relief Technology™. The high impact campaign will air nationally, including major news networks such as Fox News, MSNBC and C...
Apr 22, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the First Look Equities Summit at the City Club of Buckhead in Atlanta, GA on April 26, 2016. Dr. Gozani intends to provide an update ...
Apr 21, 2016 Year-over-Year Revenue Up 77% to $2.3 Million 8,138 Quell® Devices Shipped Quell Retail Launch Initiated with First Shipment to Target stores WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financia...
Apr 14, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it plans to issue its 2016 first quarter financial results before the opening of the market on April 21, 2016. The Company will host a conference call at 8:00 a.m., Eastern Time on April 21, 2016 to discuss its financial ...
Apr 8, 2016 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today reported continued strong media attention focusing on the company's innovative Quell® Wearable Pain Relief Technology™. Highlights include: Newsweek - This FDA-approved wearable says it relieves chron...
Mar 29, 2016 WALTHAM, Mass--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Premera Blue Cross, a leading health plan in the Pacific Northwest, will pilot the Quell® Wearable Pain Relief device within their organization. Through this innovative collaboration, Premera will provide Quell de...
Mar 28, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the 2016 Sidoti Emerging Growth Convention at the Marriott Marquis in New York, NY on March 31, 2016. Dr. Gozani intends to provide ...
Mar 28, 2016 The Only FDA Cleared 24/7 Wearable for Chronic Pain Relief Without a Prescription WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell® Wearable Pain Relief Technology™ will be featured at the Midwest Podiatry Conference to be held ...
Mar 17, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell® will be included in a new digital health initiative in over 500 Target® stores nationwide beginning in April. "We are delighted that Target will include Quell in their digital health p...
Mar 16, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell® was named Winner in the Wearable Tech category at the 19th Annual SXSW Interactive Innovation Awards, held last night in Austin, TX. The Wearable Tech award honors "new hardware that revolutionizes the con...
Mar 10, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell® Wearable Pain Relief Technology™ will be featured at the SXSW Health & MedTech Expo from March 12-13th in Austin, Texas. SXSW attendees can learn more about the latest generation of Quell ...
Mar 2, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that a major upgrade to the Quell Wearable Pain Relief technology has started shipping to consumers and healthcare providers. The latest version of the company's over-the-counter, 100% drug free chronic pain relief wearable receive...
Feb 25, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell has been selected as Best Consumer Product Winner in Digital Healthcare by Juniper Research in its annual Future Digital Awards for Technology & Innovation. Juniper's Future Digital Awards recognize innovative and ...
Feb 16, 2016 The Only FDA Cleared 24/7 Wearable for Chronic Pain Relief WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell Wearable Pain Relief Technology™ will be featured at the Combined Sections Meeting of the American Physical Therapy Association in Ana...
Feb 10, 2016 The Only FDA Cleared 24/7 Wearable for Chronic Pain Relief WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell Wearable Pain Relief Technology™ will be featured at the American Academy of Pain Medicine (AAPM) Annual Meeting in Palm Springs, Cali...
Feb 4, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference at the Convene Conference Center in New York, NY on February ...
Feb 4, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell has been selected as a finalist in the 19th Annual SXSW Interactive Innovation Awards. The SXSW Interactive Innovation Awards celebrate the most inspiring and creative innovations in the connected world. A panel ...
Jan 28, 2016 The Only FDA Cleared 24/7 Wearable for Chronic Pain Relief WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell Wearable Pain Relief Technology will be featured at the North Carolina Foot & Ankle Society's Winter Scientific Seminar to be held January ...
Jan 28, 2016 6,675 Quell® Devices Shipped, Up 48% Compared to Q3 2015 DPNCheck® Shipments at All-Time High of 54,300 Biosensors Revenue Up 94% to $2.7 Million Compared to Q4 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroM...
Jan 25, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it plans to issue its 2015 full year and fourth quarter financial results before the opening of the market on January 28, 2016. The Company will host a conference call at 8:00 a.m., Eastern Time on January 28, 2016 to ...
Jan 21, 2016 The Only FDA Cleared Wearable Device for 24/7 Chronic Pain Relief Without a Prescription WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell Wearable Pain Relief Technology will be exhibited at NY16 - Podiatric Clinical Conference and Exhibit...
Jan 21, 2016 Omron Healthcare Leads Local Initiatives WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported regulatory approval in China for DPNCheck®, a diagnostic test for peripheral neuropathy. DPNCheck is now registered as a Class II Medical Device under the ...
Jan 14, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced a high level of interest in Quell, the company's over-the-counter, 100% drug free chronic pain relief wearable at CES 2016. Highlights of the Week include: Quell was selected as one of 10 finalists in the CES ...
Jan 11, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative healthcare company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today reported preliminary financial highlights ...
Jan 6, 2016 To be Available in March 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it received a 510(k) clearance (K152954) from the U.S. Food and Drug Administration (FDA) for an upgraded version of Quell, the company's over-the-counter, 100% drug...
Jan 5, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the Biotech Showcase 2016 Conference being held in San Francisco, CA. Dr. Gozani intends to provide an overall business update and a discussion on ...
Jan 4, 2016 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced that Frank McGillin, Senior Vice President and General Manager, Consumer will participate in a panel titled "Wearables: Sleeker Smarter Faster" on Thursday, January 7 at 4:30pm (Pacific) at the 2016 CES Event in Las Vegas. Jane ...
Dec 31, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported that it has closed its previously announced private placement of preferred stock and warrants. The Company sold to a healthcare dedicated institutional investor 13,800 shares of Series C convertible preferred stock at a price of $1,000 pe...
Dec 29, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 13,800 shares of Series C convertible preferred stock at a price of $1,000...
Dec 29, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today reported the commercial launch of DPNCheck in Mexico. The initial DPNCheck order will be utilized by one of Mexico's six major government healthcare institutions to improve the detection of diabetic neuropathy and advance the overall manageme...
Dec 28, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced that Shai N. Gozani, M.D., Ph.D., President and CEO, will participate in a panel titled "Roadmap to FDA Approval" on Tuesday, January 5 at the 2016 CES Event in Las Vegas. The panel moderator is Alfred Poor, Editor of Health Tec...
Dec 23, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell is available for purchase at FSAstore.com and HSAstore.com, the only e-commerce sites stocked exclusively with eligible products for Flexible Spending Account (FSA) and Health Savings Account (HSA) members. ...
Dec 22, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell has been selected as one of 10 finalists in the Last Gadget Standing event at CES 2016. Now in its 15th year, Last Gadget Standing is one of the best loved and longest running events at the International Consumer...
Dec 17, 2015 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it has expanded distribution of the Quell Wearable Pain Relief device to The Grommet, a unique online product launch platform. "The Quell technology immediately stood out as a unique innovation that would appea...
Dec 10, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) will unveil innovative enhancements to its Quell® Wearable Pain Relief Technology™ at the 2016 CES Event January 6-9 in Las Vegas. CES is the largest consumer technology event and has served as the launch pad for innovators and breakthr...
Dec 3, 2015 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today reported growing media coverage of the Company's innovative Quell® Wearable Pain Relief Technology™. During the past two months, Quell has been featured on network television affiliates in New York, San Francisco, Philadelphia, Bo...
Dec 2, 2015 Shares of Common Stock and Listed Warrants Have Begun Trading on a Split-Adjusted Basis on The NASDAQ Capital Market BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today confirmed that it has consummated a one-for-four reverse split of its common stock. Fo...
Dec 2, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be participating in the Benchmark Micro Cap Discovery One-On-One Conference at the Palmer House Hilton in Chicago, IL on Thursday, December 10, 2015 ...
Dec 1, 2015 Shares of Common Stock and Certain Warrants Will Begin Trading on a Split-Adjusted Basis on December 2, 2015 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced a one-for-four reverse split of its common stock effective as of Tuesday, December 1, 2015. The shar...
Nov 24, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the 8th annual LD Micro Main Event at the Luxe Sunset Bel Air Hotel in Los Angeles, CA on December 3, 2015. Dr. Gozani intends...
Nov 20, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,173,581. The patent covers the core technology deployed in the DPNCheck device. The claims cover the novel integrated design of the hand-held DPNCheck device th...
Nov 12, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Canaccord Genuity Medical Technology and Diagnostics Forum at the Westin Grand Central, New York, NY on November 19, 2015. Dr. ...
Nov 11, 2015 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it was granted the American Podiatric Medical Association (APMA) Seal of Approval for its Quell Wearable Pain Relief device. "The APMA Seal of Approval is awarded after a rigorous scientific review by a group o...
Nov 9, 2015 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell will be one of 30 companies to present their latest innovations at CES Unveiled New York on November 10. CES Unveiled is produced by the Consumer Electronics Association to provide a sneak peek at the year's most innovat...
Oct 27, 2015 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) and Prism Health Care Services, Inc., an affiliate of The Alden Network, today announced an agreement under which Prism will be the exclusive distributor of Quell® wearable pain relief technology in Illinois and Wisconsin for patients in assi...
Oct 22, 2015 Approximately 4,500 Quell® Devices Shipped, Up 73% Compared to Q2 2015 DPNCheck® Shipments at Three Year High of Nearly 40,000 Biosensors Revenue Up 44% to $2.1 Million Compared to Q3 2014 WALTHAM, Mass.--(BUSINESS ...
Oct 14, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it plans to issue its 2015 third quarter financial results before the opening of the market on October 22, 2015. The Company will host a conference call at 8:00 a.m., Eastern Time on October 22, 2015 to discuss its financial ...
Oct 8, 2015 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell has been selected for the fifth annual Innovators Challenge that takes place during the Partners Healthcare's Connected Health Symposium on October 29. The Innovators Challenge was established to showcase products that a...
Oct 6, 2015 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Hammacher Schlemmer will feature Quell® Wearable Pain Relief Technology in their upcoming catalog. "Hammacher Schlemmer has a 167-year history of offering the latest and most innovative products," said Fra...
Oct 1, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), reported today that it has engaged CorProminence, LLC for investor relations services. CorProminence is a New York-based investor relations and strategic advisory firm with a business focus on small to mid-size companies. Its mandate with ...
Sep 29, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) reported today the Quell® app is now available in Google Play. Quell is an over-the-counter wearable pain relief device that utilizes proprietary non-invasive neurostimulation technology to provide relief from chronic pain. The devic...
Sep 22, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), reported that Quell was featured on ABC's Good Morning America on September 17 in a segment titled "Erase Your Pain". Good Morning America is the #1 morning show in the US, reaching nearly 5 million households each week. In the segment, Quell ...
Sep 17, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported purchases during August 2015 of the company's common stock by its Chief Executive Officer, Dr. Shai N. Gozani and Chief Financial Officer, Thomas T. Higgins. Details of these transactions may be found on the U.S. Securities and Exchange ...
Sep 15, 2015 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that its Quell Wearable Pain Relief Technology will be exhibited at the Pri-Med East Annual Conference in Boston on September 18-20, 2015. The Pri-Med East Annual Conference curriculum is developed with the American College of Phys...
Sep 9, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NURO), announced today that the Quell Wearable Pain Relief Device is now available on Amazon. "Most of our consumers are already on Amazon and appreciate the platform's convenience and first class customer service. We identified ...
Sep 8, 2015 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that its Quell Wearable Pain Relief Technology will be featured at the PAINWeek 2015 National Conference this week in Las Vegas, Nevada. PAINWeek is the nation's largest pain conference for frontline clinicians with an interest in ...
Sep 3, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NURO), a health-care company that develops wearable medical technology and point-of-care tests, reported that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Rodman & Renshaw 17th Annual Global Investment...
Sep 3, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NURO), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases and sleep disorders, announced today that the Quell Wearable Pain Re...
Aug 31, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NURO), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today announced preliminary results from a pil...
Aug 27, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NURO), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today reported that over 200,000 Medicare Adva...
Aug 18, 2015 81% of subjects reported improvement in chronic pain and overall health Two-thirds of subjects reported decreased use of pain medications Clinically significant improvement in pain relief, sleep, general activity and walking ability WAL...
Aug 13, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NURO), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today reported progress in enlisting clinician...
Aug 10, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today announced an agreement with Advantage Cons...
Aug 6, 2015 WALTHAM, Mass--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, reported purchases during July 2015 of the company's comm...
Aug 3, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, reported that Quell, launched in June 2015, is receiving...
Jul 30, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, announced today the launch of the Quell Health Cloud and...
Jul 22, 2015 The Only FDA Cleared Wearable for 24/7 Chronic Pain Relief BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell Wearable Pain Relief Technology will be featured at the APMA Annual Meeting this week in Orlando, Florida. "The breakthrough technology in ...
Jul 22, 2015 Quell Commercial Launch Milestone Achieved; Strong Early Shipments WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), today reported financial and business highlights for the quarter ended June 30, 2015. The Company operates in two primary mar...
Jul 15, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2015 second quarter financial results before the opening of the market on July 22, 2015. The Company will host a conference call at 8:00 a.m., Eastern Time on July 22, 2015 to discuss its financial result...
Jun 15, 2015 The Only FDA Cleared Wearable for 24/7 Chronic Pain Relief BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced the full commercial launch of Quell, which is now available on the Company's product website at QuellRelief.com and at select physicians' offices. Que...
Jun 2, 2015 Quell™ Wearable Pain Relief and DPNCheck® Neuropathy Test to be Featured WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patient...
May 29, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it has closed its previously announced underwritten public offering. The Company sold 147,000 units, with each unit consisting of one share of Series B convertible preferred stock and 99 warrants exercisable for 99 shares of ...
May 28, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported that it has begun to ship Quell devices to...
May 27, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today announced that it has priced an upsized underwritte...
May 13, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported that it has started shipping Quell wearable pain relief devices out of its production and fulfillment facility in Woburn, MA. The initial shipments are directed to leading doctors and thought leaders in chronic pain. The Company anticipat...
May 7, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported that it anticipates commercial shipments of the Quell wearable pain relief device will begin in June 2015. The Company also announced that it has officially started accepting pre-orders for Quell directly on its website at www.quellrelief...
Apr 28, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported today the Quell™ app is now available in the Apple app store. Quell is an over-the-counter wearable pain relief device that utilizes proprietary non-invasive neurostimulation technology to provide relief from chronic pain. The ...
Apr 21, 2015 Diabetes Product Revenue Growth, Preparation for Quell Launch WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), today reported financial and business highlights for the quarter ended March 31, 2015. The Company operates in two primary markets...
Apr 17, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2015 first quarter financial results before the opening of the market on April 21, 2015. The Company will host a conference call at 8:00 a.m., Eastern Time on Tuesday April 21, 2015 to discuss its ...
Mar 4, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced that on the day after launch it had exceeded its Quell pre-order thirty day campaign goal. The Company reported preorders for over 500 Quell devices. Demand exceeded company projections and the initial offer sold out in less than 6-hours...
Mar 2, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced a pre-order campaign on the world's largest crowdfunding platform, Indiegogo. With the campaign that begins March 2, consumers and healthcare professionals will have the ability to purchase Quell Wearable Pain Relief Technology before it...
Feb 12, 2015 Revenue Growth, Record Diabetes Product Revenue, New Product Unveiling WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), today reported financial and business highlights for the quarter and year ended December 31, 2014. The Company o...
Feb 5, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2014 full year and fourth quarter financial results before the opening of the market on February 12, 2015. The Company will host a conference call at 8:00 a.m., Eastern Time on February 12, 2015 ...
Jan 15, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO) reported that its President and Chief Executive Officer, Shai N. Gozani, M.D., Ph.D., provided an update and overview of company business activities on January 14, 2015 at the Biotech Showcase 2015 conference in San Francisco. Dr. Gozani's ...
Jan 14, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported strong interest in Quell coming out of last week's Consumer Electronics Show (CES). According to Frank McGillin, SVP and General Manager of Consumer Health at NeuroMetrix, "In the first several days that the QuellRelief.co...
Jan 9, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported today that Quell has been featured in several forums during this year's International Consumer Electronics Show (CES). Among the highlights: NeuroMetrix President and Chief Executive Officer, Shai N. Gozani, ...
Jan 7, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported today that industry insiders got their first look at Quell during day 1 of this year's International Consumer Electronics Show (CES). Quell utilizes NeuroMetrix's proprietary non-invasive neurostimulation technolo...
Jan 6, 2015 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the Biotech Showcase 2015 Conference being held in San Francisco, CA. Dr. Gozani intends to provide an overall business update and a discussion on Quell...
Dec 29, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) will unveil and demonstrate Quell, a novel wearable pain relief device at the 2015 International Consumer Electronics show (CES) January 6-9 in Las Vegas. Attendees will get their first glimpse of Quell at Booth # 73311 in the Digital Health ...
Dec 16, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it will join an exclusive number of companies to participate in CES Unveiled, the official press event of the International Consumer Electronics Show in Las Vegas in January 2015. Quell™ utilizes...
Dec 10, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering unique aspects of the Company's wearable pain relief technology. The patent addresses an important element in the ...
Dec 8, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be participating in the one-on-one Benchmark Micro Cap Discovery Conference which will be held at the Palmer House Hilton, Chicago, IL on Thursd...
Nov 19, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it will unveil Quell™, the Company's wearable pain relief device at the International Consumer Electronics Show (CES) in Las Vegas in January 2015. Quell™ Wearable Pain Relief Device (Photo: Business ...
Oct 28, 2014 Record diabetes product revenue of $0.8M Progress with over-the-counter wearable device to treat chronic pain DPNCheck® launch in Japan Overall year-over-year revenue growth of 9% WALTHAM, Mass.--(BUSINESS WIRE)...
Oct 21, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to issue it...
Sep 25, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported publication of results from a DPNCheck® study conducted at the Diabetes Research Unit of the Ipswich Hospital NHS Trust in the United Kingdom. The study by Sharma and colleagues titled "Assessment of Diabetic Neuropathy Using ...
Sep 23, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today announced that Shai N. Gozani M.D., Ph.D., NeuroMetrix President and Chief Executive Officer, will participate in the 29th Annual Meeting of The Japan Society of Diabetic Complications to be held in Tokyo on October 3 and 4, 2014. ...
Sep 3, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today announced that it has appointed Frank McGillin as Senior Vice President and General Manager, Consumer. Mr. McGillin will be responsible for development of a consumer healthcare business built on the Company's wearable therapeutic t...
Sep 2, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today announced that Shai N. Gozani M.D., Ph.D....
Jul 24, 2014 Record number of SENSUS™ devices sold FDA regulatory clearance for over-the-counter wearable technology to treat chronic pain DPNCheck® regulatory approval in Japan Year-over-year revenue growth of 16% $8...
Jul 22, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) reported today that it had reached the 10th anniversary of its initial listing on NASDAQ. NeuroMetrix debuted on NASDAQ on July 22, 2004 as a medical device company with unique technology that allowed nerve conduction studies, ...
Jul 17, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to issue it...
Jul 8, 2014 Key Step Towards Entering Consumer Healthcare Market WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its wearable technology for treatment of chronic pain received 510(k) clearance (K140333) from the U.S. Food and Drug Administration (FDA) for ...
Jun 24, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO) (the "Company" or "NURO"), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today announced that it entered...
Jun 24, 2014 Omron Healthcare Will Distribute in Japan WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep ...
Jun 10, 2014 Early Filing Achieved with Omron Healthcare China WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and s...
Jun 3, 2014 Will Feature SENSUS Pain Management System and DPNCheck Peripheral Neuropathy Test WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians ...
May 22, 2014 Omron Healthcare Showcases Product at Japan Diabetes Society Annual Meeting WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage ...
May 7, 2014 Malvern (U.K.) Diabetic Foot Conference on May 14-16, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseas...
Apr 29, 2014 WALTHAM, Mass--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, has been featured in several media outlets and in patient...
Apr 24, 2014 Record number of SENSUS™ devices sold Launch of second generation SENSUS device Strong growth in domestic DPNCheck® tests Progress toward DPNCheck launch in Japan WALTHAM, Mass.--(BUSINESS WIRE)-- ...
Apr 16, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disturbances, today said it plans to issue...
Apr 1, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care diagnostics that helps patients and physicians better manage chronic pain, nerve disorders, and associated sleep disturbances, today ...
Mar 18, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq:NURO), an innovative health care company that develops wearable medical technology and point-of-care diagnostics that help patients and physicians better manage chronic pain, nerve disorders, and associated sleep disturbances, today repor...
Mar 11, 2014 Close collaboration with Omron Healthcare in preparation of the Filing WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, reported the regulatory submission for NC...
Mar 7, 2014 Discussion of Diagnosis and Treatment of Diabetic Peripheral Neuropathy WALTHAM, Mass.--(BUSINESS WIRE)-- Shai N. Gozani, M.D., Ph.D, President and Chief Executive Officer of NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the ne...
Mar 3, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today reported publication of results from a study conducted at the University of Toronto. The study by Lee and ...
Feb 13, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders, today reported business and ...
Feb 5, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today said it plans to issue its 2013 full year and fourth quarter financial results before the opening of th...
Feb 4, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced a national distribution agreement with DJO Global for the SENSUS™ Pain Management System. SENSUS...
Jan 27, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq:NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced the launch of www.DPNCheck.com. The website is an important online resource that will help support the ...
Jan 22, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, has been featured in several media outlets that spotlighted the Company and the SENSUS™ Pain Management ...
Jan 16, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced that Jiro Nakamura, M.D., Ph.D., has joined its Scientific Advisory Board. Dr. Nakamura is ...
Jan 13, 2014 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today previewed its unaudited financial highlights for the fourth quarter ended December 31, 2013. ...
Dec 10, 2013 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, announced that it had entered into an agreement with Omron Medical Devices, a subsidiary of Omron Healthcare China, to be the...
Dec 4, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 4, 2013-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
Nov 22, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 22, 2013-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, announced the l...
Nov 7, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 7, 2013-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
Oct 23, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 23, 2013-- ...
Oct 16, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 16, 2013-- ...
Oct 15, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 15, 2013-- ...
Oct 1, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 1, 2013-- ...
Sep 30, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 30, 2013-- ...
Sep 24, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 24, 2013-- ...
Sep 3, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 3, 2013-- ...
Jul 25, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 25, 2013-- ...
Jul 17, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 17, 2013-- ...
Jul 8, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 8, 2013-- ...
Jun 10, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 10, 2013-- ...
Jun 4, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 4, 2013-- NeuroMetrix, Inc. (Nasdaq:NURO) (the "Company" or "NURO"), a medical device company focused on the diagnosis and treatment of the neurological complications of d...
Apr 25, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Apr. 25, 2013-- ...
Apr 24, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Apr. 24, 2013-- ...
Apr 17, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Apr. 17, 2013-- ...
Mar 12, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 12, 2013-- ...
Feb 19, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 19, 2013-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today reported ...
Feb 15, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 15, 2013-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced...
Feb 12, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 12, 2013-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
Jan 30, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 30, 2013-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
Jan 7, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 7, 2013-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
Jan 2, 2013 WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 2, 2013-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
Nov 29, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 29, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
Nov 27, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 27, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
Nov 1, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 1, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced ...
Oct 25, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 25, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today reported ...
Oct 15, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 15, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2012 third quarter financial results before the opening of the market on October 25, 20...
Sep 20, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 20, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has received a letter from The NASDAQ Stock Market LLC (“NASDAQ”) stating that it has ...
Sep 5, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 5, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
Aug 6, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 6, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
Jul 26, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 26, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today reported ...
Jul 19, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 19, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
Jul 18, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 18, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2012 second quarter financial results before the opening of the market on July 26, 2012...
Jun 18, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 18, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
May 31, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--May. 31, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
May 24, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--May. 24, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
May 24, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--May. 24, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
May 23, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--May. 23, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
May 17, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--May. 17, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
May 15, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--May. 15, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), ...
May 9, 2012 WALTHAM, Mass., May 09, 2012 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) www.neurometrix.com, a medical device comp...
May 1, 2012 WALTHAM, Mass., May 01, 2012 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes reported today that in separate interviews Chief Executive Officer, Shai N. Gozani, M.D., Ph.D., and Thomas T. Higgins, Chief F...
Apr 24, 2012 WALTHAM, Mass., Apr 24, 2012 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today reported business and financial highlights for the quarter ended March 31, 2012. The Company reported progress in i...
Apr 23, 2012 WALTHAM, Mass., Apr 23, 2012 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes announced that it will support a clinical study entitled "Evaluation of the Effect of Intensive Diabetes Control Through Non-surgical In...
Apr 18, 2012 WALTHAM, Mass., Apr 18, 2012 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes reported today that it has filed a premarket notification, or 510(k), with the Food and Drug Administration (FDA) for its SENSUS Pai...
Apr 17, 2012 WALTHAM, Mass., Apr 17, 2012 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2012 first quarter financial results before the opening of the market on April 24, 2012. The Company will host a conference call at 8:00 a.m., Eastern Time on April 24, 2012 to discuss its first quarter financi...
Apr 10, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Apr. 10, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes reported today t...
Mar 26, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 26, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes announced that Chief...
Mar 23, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 23, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported that i...
Mar 20, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 20, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes announced a patient initiative to support...
Mar 13, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 13, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes, today announced pla...
Mar 12, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 12, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes will be an exhibitin...
Feb 15, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 15, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today reported ...
Feb 10, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 10, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2011 fourth quarter financial results before the opening of the market on February 15, ...
Feb 8, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 8, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has priced a public offering of up to 10,500,000 Units at a price per Unit of $1.00, for ...
Jan 3, 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 3, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Offic...
Dec 28, 2011 WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 28, 2011-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced the achievement of a commercial milestone when it received its 100th NC-s...
Nov 29, 2011 WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 29, 2011-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced...
Oct 27, 2011 WALTHAM, Mass., Oct 27, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today reported business and financial highlights for the quarter and nine months ended September 30, 2011. ...
Oct 20, 2011 WALTHAM, Mass., Oct 20, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2011 third quarter financial results before the opening of the market on October 27, 2011. The Company will host a conference call at 8:00 a.m., Eastern Time on October 27, 2011 to discuss its third quar...
Oct 4, 2011 WALTHAM, Mass., Oct 04, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) today announced the appointment of Kenneth J. Snow, M.D. as Chief Medical Officer. The appointment was effective October 3, 2011. As Chief Medical Officer, Dr. Snow will be responsible for developing and managing the ...
Sep 19, 2011 WALTHAM, Mass., Sep 19, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) today reported the initiation of commercial shipments of NC-stat® DPNCheck™, a fast, accurate and quantitative point-of-care test for the evaluation of syst...
Sep 19, 2011 WALTHAM, Mass., Sep 19, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has received a letter from The NASDAQ Stock Market LLC ("NASDAQ") indicating that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The...
Sep 7, 2011 WALTHAM, Mass., Sep 07, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO), a science-based health care company improving patient care through neurotechnology, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Rodman & Renshaw Annual Global...
Sep 1, 2011 WALTHAM, Mass., Sep 01, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO), a science-based health care company improving patient care through neurotechnology, today announced the effectiveness of a one-for-six reverse stock split of its common stock. The reverse stock split, which was previously approved by t...
Aug 2, 2011 WALTHAM, Mass., Aug 02, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO), a science-based health care company improving patient care through neurotechnology, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Canaccord Genuity Growth Conferenc...
Jul 28, 2011 WALTHAM, Mass., Jul 28, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO), a science-based health care company improving patient care through neurotechnology, today reported business and financial highlights for the quarter and six months ended June 30, 2011. NeuroMetrix is focused on apply...
Jul 21, 2011 WALTHAM, Mass., Jul 21, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2011 second quarter financial results before the opening of the market on July 28, 2011. The Company will host a conference call at 8:00 a.m., Eastern time on July 28, 2011 to discuss its second quarter ...
Jul 6, 2011 WALTHAM, Mass., Jul 06, 2011 (BUSINESS WIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it met its planned marketing launch date for NC-stat®|DPNCheck™, which is a fast, accurate, and quantitative test for the evaluation of systemic neu...
Jun 20, 2011 WALTHAM, Mass., Jun 20, 2011 (BUSINESS WIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it expects to meet its planned launch date for its latest product, NC-stat®|DPNCheck™, which is a fast, accurate, and quantitative test for the evaluation of sy...
Jun 15, 2011 WALTHAM, Mass. & FT LAUDERDALE, Fla., Jun 15, 2011 (BUSINESS WIRE) --Nipro Diagnostics, Inc. and NeuroMetrix, Inc. (Nasdaq: NURO) today announced their collaboration to evaluate opportunities for NC-stat® | DPNCheck™ in retail medic...
Jun 1, 2011 WALTHAM, Mass., Jun 01, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it will exhibit at the annual meeting of The Endocrine Society in Boston on June 4-6, 2011. The exhibition will include a demonstration of its newest product - NC-stat®...
Apr 28, 2011 WALTHAM, Mass., Apr 28, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO), a science-based health care company transforming patient care through neurotechnology, today reported business and financial highlights for the quarter ended March 31, 2011. NeuroMetrix has focused its business strategy on t...
Apr 21, 2011 WALTHAM, Mass., Apr 21, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2011 first quarter financial results before the opening of the market on April 28, 2011. The Company will host a conference call at 8:00 am eastern time on April 28, 2011 to discuss its first quarter fin...
Apr 13, 2011 WALTHAM, Mass., Apr 13, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it will preview its newest product - NC-stat® | DPNCheck™ - at the Annual Meeting of the American Association of Clinical Endocrinologi...
Mar 21, 2011 WALTHAM, Mass., Mar 21, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it has formed a scientific advisory board of international experts to help guide the scientific, clinical and market development of its diabetic peripheral neuropathy (DPN) test. The device is a modified version of ...
Feb 9, 2011 WALTHAM, Mass., Feb 09, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO), a health care company transforming patient care through neurotechnology, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the Canaccord Genuity Musculoskeletal Conference at ...
Feb 3, 2011 WALTHAM, Mass., Feb 03, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO), a science-based health care company transforming patient care through neurotechnology, today reported business and financial highlights for the quarter and year ended December 31, 2010. On January 4, 2011, NeuroMetri...
Jan 26, 2011 WALTHAM, Mass., Jan 26, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2010 fourth quarter financial results before the opening of the market on February 3, 2011. The Company will host a conference call at 8:00 am eastern time on February 3, 2010 to discuss its fourth quart...
Jan 4, 2011 WALTHAM, Mass., Jan 04, 2011 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it will shift its business focus to diabetes, specifically detection and monitoring of diabetic neuropathy which is a common complication of the disease. The Company will continue to support its neurodiagnostic busi...
Page:
1
2
...
21
Next Last
 
= add release to Briefcase